The adjuvant effect of particles on allergic immune responses has been shown to increase with decreasing particle size and increasing particle surface area. Like ultrafine particles, carbon nanotubes (CNTs) have nano-sized dimensions and a large relative surface area and might thus increase allergic responses. Therefore, we examined whether single-walled (sw) and multiwalled (mw) CNTs have the capacity to promote allergic responses in mice, first in an sc injection model and thereafter in an intranasal model. Balb/cA mice were exposed to three doses of swCNT, mwCNT, as well as ultrafine carbon black particles (ufCBPs, Printex90) during sensitization with the allergen ovalbumin (OVA). Five days after an OVA booster, OVA-specific IgE, IgG1, and IgG2a antibodies in serum and the numbers of inflammatory cells and cytokine levels in bronchoalveolar lavage fluid (BALF) were determined. Furthermore, ex vivo OVAinduced cytokine release from mediastinal lymph node (MLN) cells was measured. In separate experiments, differential cell counts were determined in BALF 24 h after a single intranasal exposure to the particles in the absence of allergen. We demonstrate that both swCNT and mwCNT together with OVA strongly increased serum levels of OVA-specific IgE, the number of eosinophils in BALF, and the secretion of Th2-associated cytokines in the MLN. On the other hand, only mwCNT and ufCBP with OVA increased IgG2a levels, neutrophil cell numbers, and tumor necrosis factor-alpha and monocyte chemoattractant protein-1 levels in BALF, as well as the acute influx of neutrophils after exposure to the particles alone. This study demonstrates that CNTs promote allergic responses in mice.
Carbon nanotubes (CNTs) are used in an increasing number of consumer products (Hansen et al., 2008; Service, 2004) . CNTs are also incidental components of air pollution and are ubiquitous, especially in indoor environments where natural gas or propane cooking stoves are used (Bang et al., 2004; Murr et al., 2006) . There is, however, increasing concern regarding the potential health risks of CNTs since their unique electrical and mechanical properties may be associated with undesirable biological interactions (Kagan et al., 2006; Stern and McNeil, 2008) . Moreover, CNTs share particle characteristics such as nano-sized diameters and a large relative surface area with ultrafine particles of urban air pollution, which have adverse health effects (Pope and Dockery, 2006) . Ambient air particles are associated with development and aggravation of asthma and respiratory allergy in epidemiological studies (Annesi-Maesano et al., 2007; Morgenstern et al., 2008) , and various ultrafine particles promote immune responses to allergens in both humans and animals (reviewed in Granum and Lovik, 2002; Nygaard et al., 2004) . Few studies have addressed the effects of CNTs in the airways, but instillation, pharyngeal aspiration, and inhalation studies in rodents suggest that they cause lung inflammation, granulomas, and fibrosis Stern and McNeil, 2008) . A recent study suggests that pre-existing allergic inflammation increases the susceptibility for airway fibrosis from inhaled multi-walled carbon nanotubes (mwCNTs) in mice (Ryman-Rasmussen et al., 2008) .
Several epidemiological studies have suggested that fine and ultrafine particles cause more pronounced respiratory effects than coarse particles (Penttinen et al., 2001; Peters et al., 1997; Schwartz and Neas, 2000) . Accordingly, the adjuvant capacity of particles on allergic immune responses in mice has been shown to increase with decreasing particle size (de Haar et al., 2006; Nygaard et al., 2004) , even within the ultrafine range (Inoue et al., 2005) . The importance of particle size was demonstrated with clean, insoluble polystyrene particles, avoiding the influence of chemical or biological components (Granum et al., 2000; Nygaard et al., 2004) , and the experiments suggested that the surface area was the physical particle characteristic that best could predict the adjuvant potential of particles. We therefore hypothesized that CNTs, which have a large surface-to-mass ratio, may be potent in enhancing the antibody responses to coadministered allergens. However, the fibrous morphology of CNT differs strongly from ultrafine ''spherical'' particles, and the shape of the CNT along with other product-specific characteristics may influence their putative adjuvant effect on allergic responses.
The objective of the present study was to investigate whether single-walled carbon nanotubes (swCNTs) and mwCNTs can promote allergic immune responses. The allergic adjuvant effect of the particles was investigated in two mouse models, first in a footpad injection model (described by Lovik et al., 2007) , followed by more detailed studies in an intranasal mouse model. swCNT and mwCNT, as well as ultrafine carbon black particles (ufCBPs), were given together with the allergen ovalbumin (OVA) during sensitization. After an allergen booster, allergen-specific antibody levels in serum were determined, and in the intranasal model, additional parameters associated with an allergic airway response were examined. Furthermore, because the potential of ultrafine particles to elicit an inflammatory response in the lung has been suggested to be important for their adjuvant capacity (de Haar et al., 2005) , we determined the acute inflammatory response to the particles 24 h after a single intranasal exposure to the particles in the absence of the allergen. The present demonstration of an allergypromoting capacity of CNTs provides a basis for further evaluating the hazards of CNT in relation to the development of allergic immune responses.
MATERIALS AND METHODS
Animals. Female inbred BALB/cAnNCrl mice (Charles River, Sulzfeld, Germany) were housed, five to eight animals per cage, on BeeKay bedding (B&K Universal AS, Nittedal, Norway) in type III macrolon cages in filter cabinets (Scantainers). The animals, 6-7 weeks old, were allowed to rest for at least 1 week before entering the experiments. The mice were exposed to a 12-h/ 12-h light/dark cycle (30-60 lux in cages), regulated room temperature (20°C ± 2°C), and 40-60% relative humidity. The animals were given pelleted food (RM1; SDS, Essex, U.K.) and tap water ad libitum. The experiments were performed in conformity with the laws and regulations for experiments with live animals in Norway, and they were approved by the Experimental Animal Board under the Ministry of Agriculture in Norway.
Particle source and characteristics. swCNT and mwCNT, produced by chemical-vapor deposition method, were obtained from Sigma-Aldrich (St Louis, MO, catalog numbers 636797 and 636487, respectively). ufCBPs (Printex90), kindly provided by Degussa (Köln, Germany), were included as a positive reference particle for adjuvant activity in mice (de Haar et al., 2006) . The CNTs and the ufCBP samples were characterized by transmission electron microscopy (TEM). For the TEM sample preparation,~6-10 mg of each sample was dispersed in 2 ml ethanol by 10 min ultrasound treatment in a water bath. Thereafter, drops of the suspension were put on a holey carbon film supported by a copper grid. The particle suspensions prepared for animal exposure (see below) were also examined by TEM. The specimens were analyzed in a Jeol 2010F FEG-TEM (Jeol Ltd., Tokyo, Japan) operated at 200 kV. In the image mode, this microscope has a point resolution of~2Å . Two sets of magnifications were used: low to medium for general characterization and high magnifications for determining the internal structure of the CNTs and ufCBPs. Annular dark-field scanning transmission electron microscopy mode was also applied to determine the presence of metallic particles in the analyzed samples. This technique provides atomic number (Z) contrast due to Rutherford scattering of electrons at large angles. As the Z-difference between carbon and different metallic species is high, the latter will show bright contrast in the images. This mode was used to estimate the size of the metal impurities. The chemical composition of the metallic particles was investigated with the 'Point and Id' option of the INCA software (Oxford Instruments, Oxfordshire, U.K.) of the Energy Dispersive X-ray Spectroscopy system. In this mode, a scanning transmission electron microscopy image is recorded and x-ray spectra are taken from points (metallic particles) chosen by the operator within the image.
Specific surface area was determined by nitrogen adsorption-desorption using the Brunauer-Emmet-Teller method (Brunauer et al., 1938) . For endotoxin measurements, particles in PBS were probe sonicated (as described below), and the particle suspensions were centrifuged for 10 min at 18,000 3 g. Thereafter, the supernatants were collected and centrifuged. This was repeated twice before the endotoxin levels in the supernatants were determined by the Limulus Amebocyte Lysate (LAL) Kinetic-QCL Kit (BioWhittaker, Walkersville, MD).
Particle and allergen preparations. OVA (Gal d1; chicken egg albumin, grade VII; Sigma-Aldrich) was used as allergen after removal of endotoxin by Detoxi-Gel Endotoxin Removing Gel (Pierce, Rockford, IL). The final endotoxin level was below 0.025 ng/mg OVA, as determined by the Limulus Amebocyte Lysate (LAL) Kinetic-QCL Kit. Particle suspensions were prepared by weighing particles and carefully adding Hank's balanced salt solution (HBSS; PAA Laboratories GmbH, Linz, Austria) containing OVA to achieve final particle concentrations of 10 or 3.8 mg/ml and final OVA concentrations of 0.5 and 0.3 mg/ml in the injection and intranasal models, respectively. The tubes were kept in ice water during probe sonication (VCX 750 Ultrasonic processor with a 3 mm stepped microtip probe; Sonics, Newtown, CT) at 40% amplitude for 1.5 effective minutes in a 30-s on to 30-s off cycle. To improve the suspending of particles (Lam et al., 2004; SalvadorMorales et al., 2006) , BALB/cA mouse serum (Charles River) was added to a final concentration of 10%. The suspensions were sonicated for another 3.5 effective minutes in cycles as described above. The sonication process did not affect the length of the tubes, as judged by TEM analyses. To remove the largest particle agglomerates, all particle suspensions were left for 48 h at 4°C, and only the supernatants were used in the experiments. The particle supernatants were used undiluted for the high dose and diluted in HBSS containing OVA and mouse serum to give the medium and low doses. To determine the particle dose, supernatant samples on filters and the sediments were dried at 37°C for 3 days and weighed. However, the exact particle concentrations in the supernatants were difficult to calculate because the weight was strongly influenced by the high protein and salt content in the suspensions. In the case of no sedimentation, the high dose would be maximally 200 lg (single dose) in the injection model and 400 lg (133 lg per day for 3 days) in the intranasal model. However, sedimentation took place, and the degree of sedimentation varied between the ufCBP, swCNT and mwCNT. Thus, the amounts of particles remaining in the supernatants were not directly comparable between the particle types. Still, within each particle type, the high, medium, and low particle doses are directly related to each other. Furthermore, OVA and mouse serum proteins could bind to the various particles to different degrees and be removed by particle sedimentation. Therefore, it cannot be excluded that OVA and serum protein doses differed between the various particle types. The ufCBP had clearly less sediment than the two CNT samples, and therefore, the administered ufCBP dose was higher than the CNT doses. Moreover, the observation of very little sediment in the ufCBP samples indicates that the actual OVA dose was close to maximum for the ufCBP-exposed animals.
Injection model. The IgE adjuvant capacity of the particles was first investigated in a mouse model where allergen and particles were injected sc into the footpad (the method reviewed in Lovik et al., 2007) . Groups of eight mice were given swCNT, mwCNT, or ufCBP at low, medium, or high doses (fourfold dilutions) together with 10 lg OVA per injection. Twenty microliters of the test solutions was injected sc into the right hind footpad (heal-toe direction) using a 100-ll Hamilton syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) with a sterile 30-G needle (BD Medical Systems, Drogheda, Ireland). After 21 days, all mice were given an OVA booster (10 lg) 114 in the same footpad. On day 26, the mice were exsanguinated by heart puncture under CO 2 anesthesia, and sera were collected and stored at À20°C until quantification of OVA-specific IgE, IgG1, and IgG2a antibodies by ELISA.
Intranasal model. To study the adjuvant potency of the particles after airway exposure, we used an intranasal mouse model, somewhat modified from the model used by de Haar et al. (2005) . Groups of 10 mice were given swCNT, mwCNT, or ufCBP at low, medium, or high doses (twofold dilutions) together with 10 lg OVA per exposure on three consecutive days. The mice were anesthetized by ip injection of a mixture of 80 mg/kg Ketalar (Pfizer AB, Sollentuna, Sweden) and 10 mg/kg Narcoxyl vet (Intervet International B.V., Boxmeer, The Netherlands) and held horizontally while a total volume of 35 ll of the test solutions was deposited on the nostrils with a pipette. On days 21, 22 and 23, all mice were given an intranasal OVA booster (10 lg per day). On day 26, mice given the low and high doses were exsanguinated by heart puncture under CO 2 anesthesia, and sera were stored at À20°C until quantification of OVA-specific IgE, IgG1, and IgG2a antibodies by ELISA. The animals receiving OVA alone or together with the medium particle dose were deeply anesthetized with an overdose of thiopentone injected ip (200 mg/kg; Hospira Enterprises BV, Hoofddorp, The Netherlands). Blood was then collected by cardiac puncture, the draining cranial mediastinal lymph nodes (MLNs; Van den Broeck et al., 2006) were excised and kept in HBSS on ice, and the lungs were lavaged as described below.
Acute airway inflammation. To investigate whether the particles induced an acute inflammatory response in the lung, bronchoalveolar lavage fluid (BALF) was collected 24 h after a single intranasal exposure to the particle suspensions in the absence of the allergen. Due to practical considerations, two separate experiments were performed, in which HBSS and three doses of ufCBP were compared to either three doses of swCNT or three doses of mwCNT. Both experiments included eight mice per group.
ELISA for detection of IgE, IgG1, and IgG2a anti-OVA antibodies. OVA-specific IgE antibodies were detected in a capture ELISA as previously described (Lovik et al., 1997) and modified by Ormstad et al. (1998) , while OVA-specific IgG2a antibodies were determined using indirect ELISA as described by Nygaard et al., (2004) . The sera to be tested were for both purposes diluted 1:10. OVA-specific IgG1 was detected by coating Maxisorb microtiter plates (Nunc, Roskilde, Denmark) with 100 ll rat anti-mouse IgG1 (2.5 lg/ml in 0.05M carbonate/bicarbonate buffer, pH 9.6), followed by incubation for 1 h at room temperature and thereafter at 4°C over night. After washing with PBS/Tw (PBS containing 0.05% Tween20), the plates were incubated for 2 h at room temperature with duplicate wells containing 100 ll BALF collection, preparation, and analyses. BALF was collected, prepared, and counted for determination of total and differential cell count as previously described (Samuelsen et al., in press ). In short, the lungs were lavaged three times with 1 ml of sterile, ice-cold Ca 2þ /Mg 2þ -free Dulbecco's PBS. The BALF was centrifuged, and the supernatant from the first lavage was stored at À80°C until cytokine measurements. The cells from all three lavages were pooled and counted in a Coulter Counter Z1 (Beckman Coulter Incorporated, Fullerton, CA), and smears were prepared by spinning each sample onto cytoslides using a Cytospin Cytocentrifuge. Smears were stained using the Hemacolor rapid staining of blood smears kit (Merck KGaA, Darmstadt, Germany) according to the manufacturer's protocol. Cells were identified by standard morphology and differentiated into neutrophils, eosinophils, epithelial cells, lymphocytes, and macrophages. Four hundred cells per slide were counted by the same investigator, and the total number of each cell type was calculated using the total BALF cell number determined above. BALF levels of tumor necrosis factor-alpha (TNF-a), monocyte chemoattractant protein-1 (MCP-1), interferon-gamma (IFN-c), interleukin (IL)-5, and IL-13 were determined using BD Cytometric Bead Array (CBA) Mouse Soluble Protein Flex Sets, measured on a BD LSR II flow cytometer, and analyzed by the FCAP Array software (all from BD Biosciences, San Jose, CA) according to the manufacturer's protocol.
Lymphocyte preparation and determination of cytokine release. Within each group (10 animals), MLN cells from two animals were pooled to give a sufficient number of cells per well for determination of ex vivo cytokine production. To prepare single cell suspensions, the MLNs were torn apart with two needles and incubated in culture medium (RPMI 1640 with 5% foetal calf serum, 100 U penicillin G, and 0.1 mg/ml streptomycin) containing 1 mg/ml collagenase type 2 (Worthington Biochemical Corp., Lakewood, NJ) and 0.02 mg/ml DNAse I (grade II from bovine pancreas; Roche Diagnostics GmbH, Mannheim, Germany) in a humidified incubator at 5% CO 2 and 37°C for 15 min. The MLN fragments were resuspended with a 1-ml pipette to break up clumps and the incubation extended for another 15 min. The cell suspensions were filtered through a 70-lm cell strainer (BD Labware, Franklin Lakes, NJ), washed, and the cells counted in a Coulter Counter Z1. Cell numbers are presented as the total cell number (3 10 6 ) per animal. After incubation in culture medium with or without 1 mg/ml OVA at 37°C and 5% CO 2 for 5 days, the supernatants were removed and stored at À80°C until cytokine measurements. The levels of IL-4, IL-5, IFN-c, IL-10, and IL-12p70 were determined using BD CBA Mouse Soluble Protein Flex Sets as described above.
Data analysis. All statistical analyses were performed with SigmaStat Statistical Analysis System for Windows Version 2.03 (Jandel Scientific, Erkrath, Germany). The data were log10-transformed to meet the assumptions for running one-way ANOVA. When ANOVAs showed statistically significant differences between treatments (p 0.05), pairwise comparisons were performed by Tukey's post hoc test in order to determine which groups differed significantly from the others. Only comparisons versus the OVA control group and within each particle type were considered. Group differences were considered statistically significant if p 0.05. Table 1 summarizes the particle characteristics, as determined by the manufacturer or by the authors as indicated. The micrographs in Figure 1 illustrate how the swCNT and mwCNT samples contained long fibrous structures compared to the more spherical ufCBP. In addition to swCNT, the swCNT sample contained large amounts (~50%, as opposed to the~3% claimed by the distributor) of graphitic material of arbitrary shape as well as mwCNT (Figs. 1A and 1B) . swCNT and mwCNT in the swCNT sample were present in similar amounts. The swCNT sample also contained large amounts of cobalt metallic particles (1 nm to more than 20 nm) and low amounts of iron metallic particles (50 nm to over 500 nm). The mwCNT sample was highly homogenous (> 90%) but contained mostly fibers (as opposed to tubes), as the graphite layers made low angles with the channel direction (Fig. 1D) . These fibers had many defects (Fig. 1D) . The mwCNT sample contained lower amounts of metallic particles than the swCNT sample. Most metallic particles in the mwCNT sample consisted of nickel-iron (below 5 nm to~40 nm). The swCNT sample had the highest specific surface area, followed by the ufCBP, while the mwCNT had the lowest surface area ( Table 1) . The supernatant endotoxin levels were low for all three particle suspensions (Table 1) . Although particle-bound endotoxin would not be measured by the approach used, the low levels in the supernatants indicate that there were no large differences in the endotoxin content of the three particle samples.
RESULTS

Particle Characterization
OVA-Specific IgE, IgG1, and IgG2a Levels in Serum After
Footpad Injection of Particles and OVA After footpad injection of particles together with the allergen OVA, both swCNT, mwCNT and ufCBP significantly increased the levels of OVA-specific IgE at medium and high particle doses compared to OVA alone ( Fig. 2A) . Only mwCNT significantly increased the IgE levels at the lowest dose. Similar results were obtained for the OVA-specific IgG1 levels (Fig. 2B) . Although most pronounced for the ufCBP, all particle types showed a dose-dependent increase in IgE and IgG1 levels. The OVA-specific IgG2a levels were low, but statistically significantly increased for the high(est) doses of mwCNT and ufCBP (Fig. 2C) .
Intranasal Exposure to Particles and OVA To further examine the allergic adjuvant potency of the CNTs, mice were intranasally exposed to swCNT, mwCNT, and ufCBP with OVA, followed by an OVA booster. All three particle types significantly increased the OVA-specific IgE levels at all three doses compared to OVA alone (Fig. 3A) . However, at the doses employed, the two CNTs induced a significant dose-dependent IgE response, while the ufCBP appeared to have reached a plateau level at which increased particle doses gave no further increase in IgE levels. Similar results were obtained for the OVA-specific IgG1 response, but the dose-response relationship was less pronounced (Fig. 3B) . As in the footpad injection model, only the higher doses of upper quantitative detection limits for the ELISA assays. Asterisk denotes a statistically significant difference compared to the OVA group, whereas brackets denote statistically significant differences between different doses of the same particle.
NANOTUBES AND ALLERGY mwCNT and ufCBP, but not swCNT, significantly increased the levels of OVA-specific IgG2a (Fig. 3C) .
Airway Inflammation After Intranasal Exposure to Particles and OVA
After intranasal exposure to OVA and the medium doses of swCNT, mwCNT, and ufCBP, followed by an OVA booster, airway inflammation was examined by determining cell numbers and cytokine levels in BALF. For all three particle types, the total number of cells was significantly higher in the groups receiving particles with OVA compared to the OVA alone group (Fig. 4A, right panel) . Only very low numbers of lymphocytes, neutrophils, and eosinophils were observed in animals exposed to OVA alone (Fig. 4A) . All three particle types with OVA significantly increased the number of neutrophils, lymphocytes, and eosinophils compared to OVA alone but to different degrees. In agreement with their ability to strongly increase the IgE levels, only the swCNT and mwCNT with OVA strongly increased the number of eosinophils after the OVA booster. On the other hand, only exposure to mwCNT and ufCBP with OVA gave a pronounced increase in the number of neutrophils, accompanied by increased levels of MCP-1 and the proinflammatory cytokine TNF-a (Figs. 4A and 4B, respectively). Although all three particle types apparently were taken up by macrophages (as observed by light microscopy of the BALF cells, data not shown), only mwCNT with OVA significantly increased the number of macrophages. The relative number of epithelial cells did not differ between groups (data not shown). Only marginal levels of IFN-c, IL-5, and IL-13 were detected in BALF (data not shown).
Cellular Response in the Draining MLN After Intranasal
Exposure to Particles and OVA Cellular responses in the draining MLN were determined after intranasal exposure to the medium doses of swCNT, mwCNT, and ufCBP, followed by an OVA booster. Both swCNT, mwCNT and ufCBP were present in the MLN, visually observed as a darkening of the MLN (data not shown). The total number of cells in the MLN was significantly increased after intranasal exposure to all three particle types with OVA compared to OVA alone (Fig. 5A) . After ex vivo OVA stimulation of the MLN cells, the levels of IL-10 in the supernatants were significantly increased by all particle types with OVA but appeared to be higher after exposure to the CNT than to ufCBP (Fig. 5B) . OVA-induced IL-5 secretion was significantly increased only in the groups exposed to the CNTs with OVA, and a similar but less pronounced response was seen for IL-4 (Figs. 5D and 5C , respectively). The swCNT also increased the OVA-induced IFNc secretion weakly but significantly. However, this increase was accompanied by a similarly weak tendency of increased IFN-c secretion from the unstimulated cells (Fig. 5E ). IL-12p70 secretion was barely detectable and did not differ significantly between groups (data not shown).
FIG. 3.
Serum levels of OVA-specific IgE (A) and IgG1 (B) and IgG2a (C) on day 26 after intranasal exposure to 10 lg OVA (per day) alone or together with particles on day 0, 1, and 2. swCNT (light gray bars), mwCNT (dark gray bars), and ufCBP (black bars) in low, medium, and high doses were used. On day 21, 22, and 23, all mice were boosted intranasally with 10 lg OVA (per day). Values (ng or arbitrary units [AU] per ml) for individual mice (circles) and median values (columns) for groups of 10 mice are shown. The dotted lines indicate the lower and upper quantitative detection limits for the ELISA assays. Asterisk denotes a statistically significant difference compared to the OVA group, whereas brackets denote statistically significant differences between different doses of the same particle.
Acute Inflammatory Response After a Single Intranasal Exposure to Particles
To investigate whether the capacity of the particles to elicit an acute inflammatory response in the lung could reflect their adjuvant potency, broncheoalveolar lavage was performed 24 h after a single intranasal exposure to the particles (in the absence of OVA). The number of neutrophil cells in BALF was increased in a dose-dependent fashion by ufCBP in two independent experiments (Fig. 6, left and right panel) . Also the mwCNT significantly increased the number of neutrophils (Fig.  6, right panel) , whereas the swCNT did not (Fig. 6, left panel) . No or low numbers of lymphocytes and eosinophils were detected, and the numbers of macrophages and epithelial cells were only marginally affected by the highest doses of mwCNT and ufCBP (data not shown).
DISCUSSION
CNTs share particle characteristics like nano-sized dimensions and high relative surface area with ambient ultrafine particles, which have been associated with development and aggravation of respiratory allergies (reviewed in Granum and Lovik, 2002) . We therefore investigated whether also CNTs have the capacity to promote allergic immune responses. Both swCNT and mwCNT together with OVA increased serum levels of allergen-specific IgE, the number of eosinophils in BALF, and the secretion of Th2-associated cytokines in the MLN, all being important mediators in allergic airway responses. CNT demonstrated adjuvant effect on allergenspecific antibody responses also after sc injection into the footpad, illustrating the usefulness of the footpad model as a hazard identification model for respiratory adjuvants (reviewed by Lovik et al., 2007) .
The two CNTs seemed to differ from the ufCBP by inducing an apparently stronger, CNT dose-dependent increase in OVAspecific IgE levels after intranasal exposure. Accordingly, pronounced eosinophilic lung inflammation and Th2-associated cytokine responses were observed only after exposure to the CNTs. Although the ufCBP also significantly promoted IgE production, they induced relatively low IgE levels, which seemed to reach a plateau at low doses and were associated with Cell numbers (A) and cytokine levels (B) in BALF collected 26 days after intranasal exposure of mice to particles and allergen, following allergen booster, as described in Figure 3 . Only animals exposed to OVA alone or together with the medium dose of swCNT, mwCNT, and ufCBP were lavaged. The left panel of (A) shows cell numbers determined by differential counts, whereas the right panel shows the total number of cells in BALF as determined by Coulter cell counter. Mean values and SD for groups of 10 mice are shown. Asterisk denotes a statistically significant difference compared to the OVA group. NANOTUBES AND ALLERGY low eosinophil numbers and Th2 cytokine secretion. The apparently stronger allergic adjuvant effect of CNT compared to ufCBP was probably not due to a higher particle or OVA dose since the particle and OVA mass dose most likely was highest for the ufCBP sample (as described in the Materials and Methods). Moreover, a further three times higher dose of ufCBP only marginally increased the IgE levels (data not shown). Similar differences between the IgE adjuvant capacity of the two CNTs and ufCBP have also been observed in recent experiments where the particle and OVA doses are equal (i.e., suspensions used without the sedimentation step; Nygaard et al., in preparation) . The IgE plateau observed after intranasal exposure to ufCBP with OVA was not observed after injection into the footpad. The intranasal exposure route differ from the injection route by a number of factors, such as spread of the exposure volume over a larger area, different clearance mechanisms possibly affecting the actual allergen dose reaching the immunocompetent cells, or particle-induced modulation of the adaptive immune response by the airway mucosal lining. Although a recent study demonstrates similar airway responses after inhalation of aerosolized and aspiration of suspended swCNT , artifacts due to the intranasal administration of a particle suspension cannot be excluded. Therefore, inhalation studies would be beneficial to determine the dose-response relationship as well as the impact of various particle characteristics on the observed adjuvant effect.
The three particle types, swCNT, mwCNT, and ufCBP, apparently induced qualitatively different immune responses in the lung. All particles together with OVA increased the number of lymphocytes in BALF after the OVA booster, indicating the presence of an inflammatory response. Yet, while high levels of OVA-specific IgE, high numbers of eosinophils, and increased Th2 cytokine production were seen after exposure to the swCNT and mwCNT, strongly increased neutrophil numbers, 
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MCP-1 and TNF-a levels, and OVA-specific IgG2a levels were induced only after exposure to ufCBP and mwCNT. Likewise, ufCBP and mwCNT, but not swCNT, induced an acute influx of neutrophils 24 h after a single exposure to the particles in the absence of allergen. Although speculative, there seem to be an association between the particles' ability to induce TNF-a production, a neutrophil type of airway inflammation, and OVA-specific IgG2a production. Our data suggest that the strong adaptive immune response promoted by CNT is not necessarily associated with a particle-induced early neutrophil inflammation, as previously suggested for ultrafine particles (de Haar et al., 2005) . Oxidative stress, increased antigen presentation, and allergen carrying are other factors suggested to be important for the IgE adjuvant effect of ultrafine particles (de Haar et al., 2008; Parnia et al., 2002; Wan and Diaz-Sanchez, 2007) , but their role for the adjuvant effect of CNT requires further studies.
The physicochemical particle characteristics responsible for the apparently stronger allergic adjuvant activity of the swCNT and mwCNT compared to the ufCBP are not known. The total surface area was highest for the swCNT, and higher for the ufCBP than for the mwCNT, and could therefore not explain the differences in adjuvant potency. The fibrous shape of the CNTs, however, could be of importance since longer mwCNT have been reported to give higher residential time in the lungs and stronger sc inflammatory responses than shorter mwCNT (Muller et al., 2005; Sato et al., 2005) . Other properties shown to affect CNT airway toxicity in vivo or in vitro are structural defect sites (Muller et al., 2008) , degree of agglomeration Wick et al., 2007) , charge, coating, metal contaminants, as well as protein and thus allergen-binding properties (reviewed in Stern and McNeil, 2008) . Although the relation between airway toxicity and adjuvant effect is not clear, several of the mentioned characteristics may also influence the allergy-promoting potential of CNT.
Engineered nanoparticles collected as dry powder are in general hard to disperse (Powers et al., 2007) . A great variety of suspension methods have been described in the literature, and the degree of particle agglomeration has been shown to be strongly influenced by the particle characteristics and the protein and lipid content of the suspension medium (Buford et al., 2007) . Large particle agglomerates are of less relevance for airway exposure and demonstrate an altered airway deposition pattern compared to smaller agglomerates of CNT . To avoid influence of the largest nanoparticle agglomerates, agglomerates were removed by sedimentation and mice were exposed to the particle suspension supernatant. Removal of particle agglomerates, however, made it difficult to determine the accurate particle dose (as described in the Materials and Methods). Furthermore, particles differ in their quantitative and qualitative protein-binding properties (Dutta et al., 2007; Salvador-Morales et al., 2006) . Thus, OVA and mouse serum proteins may bind to and be removed by the sedimented particles to different degrees. We cannot exclude the possibility that OVA and serum protein doses also differed between the highest doses of the various particle types. Still, our study clearly demonstrates a capacity of swCNT and mwCNT to promote allergic responses in the airways.
Previous studies suggest that nano-sized particles are potent adjuvants for allergen-specific IgE production and eosinophil inflammations in the lung (de Haar et al., 2006; Nygaard et al., 2004; Takano et al., 1997) . We now present data indicating that swCNT and mwCNT act as allergy adjuvants and may be even more potent than 'spherical' particles like ufCBP. It is therefore important to identify the physicochemical characteristics responsible for their strong adjuvant effect, both with regard to hazard assessment and how these particle characteristics can be altered to reduce the biological impact of engineered nanoparticles. NANOTUBES AND ALLERGY their excellent technical assistance. We also appreciate the help from Å se Eikeset, Bodil Hasseltvedt, Berit A. Stensby, and the staff of the animal facilities of the Norwegian Institute of Public Health. The generous provision of Printex90 particles by Degussa is gratefully acknowledged. Conflict of interest: The funding organization does not have control over the resulting publication.
